CD274 and neoplasm: Anti-PD-1 antibodies, which target the inhibitory ligand PD-L1 on tumor cells and thus increase the cell functioning previously burdened by PD-L1, are FDA-approved and have been shown to potentiate the effects of PARPi through crosstalk [141,142].